PDTM-16. PEDIATRIC HIGH GRADE GLIOMA RESOURCES FROM THE CHILDREN’S BRAIN TUMOR TISSUE CONSORTIUM (CBTTC) AND PEDIATRIC BRAIN TUMOR ATLAS (PBTA)

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2019-11, Vol.21 (Supplement_6), p.vi190-vi190
• Main Authors: Ijaz, Heba, Koptyra, Mateusz, Gaonkar, Krutika, Lynne Rokita, Jo, Baubet, Valerie, Tauhid, Lamiya, Zhu, Yuankun, Brown, Miguel, Lopez, Gonzalo, Zhang, Bo, Diskin, Sharon, Vaksman, Zalman, Mason, Jennifer, Appert, Elizabeth, Lilly, Jena, Lulla, Rishi, De Raedt, Thomas, Heath, Allison, Felmeister, Alex, Raman, Pichai, Nazarian, Javad, Santi, Mariarita, Storm, Phillip, Resnick, Adam, Waanders, Angela, Cole, Kristina
• Format: Article
• Language: English
• Subjects: Pediatric Tumors
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/noz175.792

Abstract BACKGROUND Pediatric high grade glioma (pHGG) remains a fatal disease. Access to richly annotated biospecimens and patient derived tumor models will accelerate pHGG research and support translation of research discoveries. This work describes the pediatric high grade glioma set of the Children’s Brain Tumor Tissue Consortium (CBTTC) from the first release of the Pediatric Brain Tumor Atlas (PBTA). METHODS pHGG tumors with associated clinical data and imaging were prospectively collected through the CBTTC and analyzed as the Pediatric Brain Tumor Atlas (PBTA) with processed genomic data deposited into PedcBioPortal for broad access and visualization. Matched tumor was cultured to create high grade glioma cell lines analyzed by targeted and WGS and RNA-seq. A tissue microarray (TMA) of primary pHGG tumors was also created. RESULTS The pHGG set includes 87 collection events (73 patients, 60% at diagnosis, median age of 9 yrs, 55% female, 46% hemispheric). Operative reports, pathology reports and histology images are available for nearly all cases. Pre- and post-operative MRI images and reports are also available for a subset. Tumor WGS/RNAseq is available for 70 subjects. Analysis of somatic mutations and copy number alterations of known glioma genes were of expected distribution (36% H3.3, 47% TP53, 24% ATRX and 7% BRAFV600E variants). In our panel of pHGG, six patients (8 tumors) harbored germline mismatch repair mutations with tumor hyper-mutation. A pHGG TMA (n=77), includes 36 patient tumors with matched sequencing. At least one established glioma cell line was generated from 23 patients (32%). Unique reagents include those derived from a H3.3 G34R glioma and from tumors with mismatch repair deficiency. CONCLUSION The CBTTC and PBTA have created an openly available integrated resource of over 2,000 tumors, including a rich set of pHGG primary tumors, corresponding cell lines and archival fixed tissue to advance translational research for pHGG.